Ovarian Cancer

Olaparib maintenance monotherapy not only delays disease progression but also improves overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation. Read Article ›

Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant. Read Article ›

In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death. Read Article ›

Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status. Read Article ›

Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer. Read Article ›

In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities. Read Article ›

Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy. Read Article ›

Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer. Read Article ›

Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant. Read Article ›

In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer. Read Article ›

Page 3 of 10

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: